Cambridge, United States
Kira Pharmaceuticals, founded in 2017, stands at the forefront of the biotech industry with its mission to pioneer a world free from complement disease. Leveraging its innovative LOGIC platform, this clinical-stage company has established a robust pipeline of nine novel complement assets, addressing validated targets across the complement cascade.
With headquarters in Cambridge, Massachusetts, and additional offices in Suzhou, Shanghai, China, and Australia, Kira Pharmaceuticals is well-positioned globally. The team comprises seasoned experts in complement biology, drug development, and protein engineering, making it uniquely equipped to overcome some of the toughest challenges in the complement space.
In its latest investment round—a $53.50M Series B on January 07, 2021—the company attracted high-profile investors including RA Capital Management, Qiming Venture Partners USA, Vivo Capital, Foresite Capital, Quan Capital, and APlus Partners, signalling strong confidence in its potential impact and industry leadership.
